ClinicalTrials.gg
RecruitingNCT07763418Updated Oct 1, 2026

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

A Phase 1 interventional study of Golcadomide in Kidney Failure, Chronic, sponsored by Bristol-Myers Squibb. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 1, 2026Now RecruitingStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 765 studies in Kidney Failure, Chronic with a site in United States — 65 open to participants now, 97 under way, 9 of them phase 3. Kidney Failure, Chronic · United States.

Planned enrollment
391st of 638
30 · median 48
Started
2026
with 21 others
Phase 1
89 of 765
8 open now
Primary completion
2026-12
later than 20 of 96 live
Registered
760th of 765
by date

Among the 765 studies in Kidney Failure, Chronic with a site in United States, this one is the 391st largest by planned enrollment of the 638 interventional ones that give a count, is one of 22 that started in 2026, is one of 89 in phase 1, reaches primary completion later than 20 of the 96 other live ones, and was the 760th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

65 of the 765 studies in Kidney Failure, Chronic with a site in United States are open now. Recruiting first, the newest first:

59 more — sign in →

All 65 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 765 studies in Kidney Failure, Chronic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.

03

Conditions studied

  • Kidney Failure, Chronic

Keywords

  • Golcadomide
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have severe renal impairment (RI).
  • Participant must have end-stage renal disease (ESRD).
  • Participant must be healthy male and female participants not of between 18 and 84 years of age (inclusive) with a between 18 and 40 kg/m2, (inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

  • Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study
  • Known or suspected active disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Group A

    Drug: Golcadomide

  • Experimental
    Group B

    Drug: Golcadomide

  • Experimental
    Group C

    Drug: Golcadomide

Interventions

  • Specified dose on specified days

    Also known as: BMS-986369, CC-99282

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    Time frame: Up to Day 44

  2. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to Day 44

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T))

    Time frame: Up to Day 44

  4. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))

    Time frame: Up to Day 44

Secondary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to Day 60

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to Day 60

  3. Number of participants with physical examination (PE) abnormalities

    Time frame: Up to Day 44

  4. Number of participants with vital sign abnormalities

    Time frame: Up to Day 44

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Day 44

  6. Number of participants with clinical safety laboratory abnormalities

    Time frame: Up to Day 44

  7. Dialysate clearance of golcadomide from plasma (CLD)

    Time frame: Day 1

07

Study locations

3 of 3 sites recruiting
  • Arizona Clinical Trials - Chandler
    Chandler, Arizona 85225, United States
    Recruiting
    • Anita Kohli, Site 0003 · Contact434-825-0921
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
    Recruiting
    • Robert Perry, Site 0002 · Contact305-698-4500
  • Orlando Clinical Research Center OCRC
    Orlando, Florida 32809-3017, United States
    Recruiting
    • Thomas Marbury, Site 0001 · Contact407-257-3462
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 3 months is below that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 13, 2026
StartActual
Sep 8, 2026was Aug 2026
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 28, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 United States)
  • Arizona Clinical Trials - Chandler · Chandler, United States
  • Panax Clinical Research · Miami Lakes, United States
  • Orlando Clinical Research Center OCRC · Orlando, United States
Show 3 removed
  • Local Institution - 0003 · Chandler, United States
  • Local Institution - 0002 · Miami Lakes, United States
  • Local Institution - 0001 · Orlando, United States
Oct 1, 2026
Start date
Aug 24, 2026→Sep 8, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Recruiting
    3 sites added, 3 sites removed
    Show 3 added (3 United States)
    • Arizona Clinical Trials - Chandler · Chandler, United States
    • Panax Clinical Research · Miami Lakes, United States
    • Orlando Clinical Research Center OCRC · Orlando, United States
    Show 3 removed
    • Local Institution - 0003 · Chandler, United States
    • Local Institution - 0002 · Miami Lakes, United States
    • Local Institution - 0001 · Orlando, United States
    Start date Aug 24, 2026→Sep 8, 2026 (now actual)
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07763418
Responsible party
Sponsor
First posted
Aug 13, 2026
Start date
Sep 8, 2026
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 28, 2026 (estimated)
Last update
Oct 1, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golcadomide

Start the discussion